Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 11/20 | 0.35 |
| ▸ | HTR1D | P28221 | 11/20 | 0.35 |
| ▸ | HTR1B | P28222 | 11/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430548 | 0.89 | THRB (0.38) | THRBHTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL430475 | 0.80 | TP53 (0.45) | THRBHTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL431604 | 0.79 | HTR1A (0.50) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL29810722 | 0.78 | THRB (0.40) | THRBBRD9BRD7CYP1A2 | |
| SCHEMBL27238490 | 0.78 | THRB (0.40) | THRBBRD9BRD7CYP1A2 | |
| SCHEMBL27238518 | 0.78 | THRB (0.40) | THRBBRD9BRD7 | |
| SCHEMBL29810711 | 0.78 | THRB (0.40) | THRBBRD9BRD7 | |
| SCHEMBL4169835 | 0.77 | HTR1A (0.47) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429130 | 0.73 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429648 | 0.73 | HTR1A (0.52) | HTR1AHTR1DHTR1BSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | THRB 824/4885HTR1A 7/4885HTR1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.